Insomnia Market Report 2022, Industry Size, Share, Growth, Major Players and Forecast Till 2027

IMARC Group has recently released a new research study “insomnia market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

What are the growth prospects of the insomnia Industry?

The global insomnia Market size reached US$ 4.87 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of  US$ 5.93 Billion  by 2027, exhibiting a growth rate (CAGR) of 3.22% during 2022-2027.

What is a insomnia market ?

Insomnia refers to a sleep disorder that can lower energy levels and affect the mood, health, work performance, and overall life quality of an individual. Its causes include stress, long travels, hectic work schedules, poor sleep habits, binge eating, etc., and excessive consumption of nicotine, caffeine, alcohol, etc.

Request For Sample Report:

Insomnia can also be associated with mental health disorders, including post-traumatic stress and the use of drugs, such as antidepressants for asthma or blood pressure and over-the-counter (OTC) for pain relief, allergies, cold, etc. Its treatment options, including cognitive-behavioral therapy (CBT), over-the-counter (OTC) sleep aids, and prescription medications, such as Eszopiclone and Ramelteon, are currently available across various countries.

Covid-19 Impact:

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

What are the major market drivers in the Insomnia Market: 

The increasing prevalence of social isolation, work challenges, and family obligations, owing to the sudden outbreak of the COVID-19 pandemic, is among the key factors stimulating the insomnia market. Apart from this, the rising incidences of stressful events that impact the sleep patterns of individuals are also propelling the market growth.

Besides this, the inflating cases of medical conditions, such as chronic pain, cancer, diabetes, heart disease, asthma, gastroesophageal reflux disease (GERD), overactive thyroid, Parkinson’s disease, and Alzheimer’s disease, are further fueling the global market.

Additionally, hormonal shifts during the menstrual cycle and menopause can lead to the risk of developing insomnia, which is also driving the market growth. Moreover, the elevating investments in testing new treatments, interventions, and tests to prevent, detect, treat, and manage insomnia are expected to positively influence the insomnia market over the forecasted period.

Insomnia Market Report Scope
Report Coverage Details
Market size value in 2021 US$ 4.87 Billion
Market forecast in 2027 US$ 5.93 Billion
Growth Rate CAGR of 3.22% from 2022 to 2027
Base year for estimation 2021
Historical data 2016-2021
Forecast period 2022-2027
Report coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, And Trends
Segments covered  Therapy Type, Drug Class And Distribution Channel.
Regional scope United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Key companies profiled Astellas Pharma Inc., Aurobindo Pharma Limited, Biocodex, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Merck & Co. Inc., Neurim Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.), Takeda Pharmaceutical Company Limited and Vanda Pharmaceuticals Inc.
Market Dynamics Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,
Customization purview If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.


Report Segmentation:

The report has been segmented the market into following categories:

Breakup by Therapy Type:

Non-Pharmacological Therapy

  • Hypnotherapy
  • Cognitive Behavioral Therapy
  • Medical Devices
  • Others

Pharmacological Therapy

  • Prescription Sleep Aids
  • Over-The-Counter Sleep Aids

Breakup by Drug Class:

  • Antidepressants
  • Melatonin Antagonist
  • Benzodiazepines
  • Nonbenzodiazepines
  • Orexin Antagonist
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Geography:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

List of Major Key Players:

The major players in the market are

Astellas Pharma Inc.

Aurobindo Pharma Limited

Biocodex, Eisai Co. Ltd.

Mallinckrodt Pharmaceuticals

Merck & Co. Inc.

Neurim Pharmaceuticals Inc.

Pfizer Inc., Sanofi S.A.

Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.),

Takeda Pharmaceutical Company Limited

and Vanda Pharmaceuticals Inc.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Chris Greenwalty
Kate Johnson is a content writer, who has worked for various websites and has a keen interest in Online Signals Report and Stock portfolio generator. She is also a college graduate who has a B.A in Journalism. Read More: Fin Scientists >> Read More: Stocks Signals Mobile App >> Read More: Crypto Signals >> Read More: Crypto Trade Signals App >> Read More: Trade Signal Buy and Sell

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in Business